CRADBS Stock Overview
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
C-Rad AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr45.95 |
| 52 Week High | kr45.95 |
| 52 Week Low | kr45.95 |
| Beta | 1.14 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRADBS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.0% |
| 1Y | n/a | -9.2% | 3.0% |
Return vs Industry: Insufficient data to determine how CRADBS performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how CRADBS performed against the UK Market.
Price Volatility
| CRADBS volatility | |
|---|---|
| CRADBS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CRADBS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CRADBS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 70 | Tim Thurn | www.c-rad.com |
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery.
C-Rad AB (publ) Fundamentals Summary
| CRADBS fundamental statistics | |
|---|---|
| Market cap | kr1.13b |
| Earnings (TTM) | kr12.20m |
| Revenue (TTM) | kr259.65m |
93.0x
P/E Ratio4.4x
P/S RatioIs CRADBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRADBS income statement (TTM) | |
|---|---|
| Revenue | kr259.65m |
| Cost of Revenue | kr85.32m |
| Gross Profit | kr174.33m |
| Other Expenses | kr162.13m |
| Earnings | kr12.20m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 28, 2022
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 67.14% |
| Net Profit Margin | 4.70% |
| Debt/Equity Ratio | 0% |
How did CRADBS perform over the long term?
See historical performance and comparison